[The possibilities of using himantane in the treatment of Parkinson's disease].
The domestic drug himantane has been used as a monotherapy in dosage 25 mg daily during 12 weeks in patients with Parkinson's disease. Patient's state has been assessed using clinical, electromyographic, electroneuromyographic, EEG and psychometric (UPDRS and other scales) methods. The preparation used is well tolerated, induces the significant decrease of movement disorders, i.e. tremor, and exerts a positive effect on emotional and personality disturbances. The clinical changes have been confirmed by electroneuromyographic data and EEG.
Katunina
E A
EA
Petrukhova
A V
AV
Avakian
G N
GN
Val'dman
E A
EA
Nerobkova
L N
LN
Voronina
T A
TA
Saiadian
Kh S
KhS
D000218:Adamantane / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004569:Electroencephalography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology*; D012720:Severity of Illness Index; D014202:Tremor / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology
D000978:Antiparkinson Agents; C122112:N-(2-adamantyl)hexamethylenimine; D000218:Adamantane